Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis

By Heizmann M.   Baerlocher G.M.   Steinmann F.   Horber F.F.   Wuillemin W.A.  

Thrombosis Research, Vol. 106, Iss. 4, 2002-05 ,pp. : 179-181

Elsevier

Access to resources Recommend Favorite

VERY LOW DOSES OF UNFRACTIONATED HEPARIN POTENTIATE THE ANTI-Xa ACTIVITY OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN)

By Perez-Requejo J.L.   Lucena-Solano O.   Perez-Garcia M.   Santarelli M.T.  

Thrombosis Research, Vol. 85, Iss. 3, 1997-02 ,pp. : 259-265

Elsevier

Access to resources Recommend Favorite

DETERMINATION OF THE ANTI-FACTOR Xa ACTIVITY OF THE SYNTHETIC PENTASACCHARIDE SR 90107A/ORG 31540 AND OF TWO STRUCTURAL ANALOGUES

By Lormeau J.C.   Herault J.P.   Gaich C.   Barzu T.   van Dinther T.G.   Visser A.   Herbert J.M.  

Thrombosis Research, Vol. 85, Iss. 1, 1997-01 ,pp. : 67-75

Elsevier

Access to resources Recommend Favorite

Body Weight Does Not Predict for Anti-Xa Levels after Fixed Dose Prophylaxis with Enoxaparin After Orthopedic Surgery - The post-arthroplasty screening study

By Kovacs M.J.   Weir K.   MacKinnon K.   Keeney M.   Brien W.F.   Cruickshank M.K.  

Thrombosis Research, Vol. 91, Iss. 3, 1998-08 ,pp. : 137-142

Elsevier

Access to resources Recommend Favorite

Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series

By Deal Eli  

Journal of Thrombosis and Thrombolysis, Vol. 32, Iss. 2, 2011-08 ,pp. : 188-194

Springer Publishing Company

Access to resources Recommend Favorite